Table 2 Multivariate Cox’s proportional hazards models for relapse-free survival in NTUH cohort (A) and breast cancer-specific mortality in METABRIC cohort (B) and comparison of added prognostic information by TP53 in the two cohorts (C).

From: TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays

(A) Relapse-free survival

Characteristic

HR

95% CI

P

T stage

 T3 v T1 / T2

2.65

1.78–3.94

<0.001

N stage

 N0 v N1 / N2

0.47

0.32–0.70

<0.001

 N3 v N1 / N2

1.64

1.05–2.57

0.030

IHC4 score

 High/intermediate v low

1.90

1.32–2.73

<0.001

TP53 status

 Mutant v wild

1.63

1.14–2.32

0.007

(B) Breast cancer-specific mortality

Age

 <45/ >65 v 45–65 years

1.71

1.27–2.29

<0.001

T stage (ordinal)

 Increased one unit (1 v 2 v 3)

1.45

1.11–1.91

0.007

N stage (ordinal)

 Increased one unit (0 v 1 v 2. v 3)

1.58

1.33–1.87

<0.001

HER2 overexpression

 Yes v no

1.58

1.12–2.23

0.010

PAM50

 Luminal B v luminal A

1.38

0.95–1.99

0.090

 HER2 enriched v luminal A

1.73

1.04–2.87

0.036

 Basal-like v luminal A

1.74

1.12–2.70

0.013

 Normal-like v luminal A

1.90

0.99–3.65

0.054

TP53 status

 Mutant v wild

2.35

1.64–3.36

<0.001

(C)

Cohort

∆ LR-χ 2

P

NTUH

  

 T stage + N stage + IHC4 + TP53 v T stage + N stage + IHC4 (df=1)

1668.3 − 1659.7 = 8.6

0.002

METABRIC

  

 age + T stage + N stage + HER2 + PAM50 + TP53 v age + T stage + N stage + HER2 + PAM50 (df=1)

2261.3 − 2242.4 = 18.9

< 0.001

Back to article page